Daily Ards Research Analysis
Analyzed 2 papers and selected 3 impactful papers.
Summary
Today's papers span preclinical immunology and critical care outcomes. A mechanistic mouse/cell study shows uridine ameliorates LPS-induced lung injury by promoting M2 alveolar macrophage polarization via STAT6, improving survival. A large retrospective cohort of severe TBI patients undergoing SDH evacuation found intracranial pressure monitoring did not reduce in-hospital mortality but was associated with longer hospital stay and higher complication rates, including ARDS.
Research Themes
- Macrophage polarization and immunometabolism in ALI/ARDS
- Reappraisal of intracranial pressure monitoring in severe TBI
- Translational trajectory from preclinical immunology to critical care
Selected Articles
1. Role of uridine triggering M2 macrophage polarization to alleviate LPS-induced acute lung injury through the STAT6 signaling pathway.
In mouse LPS-induced ALI and LPS-stimulated MH-S cells, uridine reduced lung edema, neutrophilic activity, and inflammatory mediators, and improved survival. Mechanistically, it promoted alveolar macrophage M2 polarization with STAT6 phosphorylation, nominating STAT6 signaling as a therapeutic axis.
Impact: This preclinical study links a simple nucleoside, uridine, to macrophage programming via STAT6, yielding survival benefits in ALI. It provides a tractable immunometabolic strategy for ARDS-focused drug development.
Clinical Implications: While preclinical, the data support testing uridine or STAT6-targeted approaches as adjunctive therapies for ALI/ARDS. Dose, timing, safety, and STAT6 dependency must be verified in higher-order models and early-phase trials.
Key Findings
- Uridine reduced lung index, wet-to-dry ratio, MPO activity, protein leakage, and pro-inflammatory cytokines in LPS-induced ALI.
- Uridine improved survival in mice subjected to LPS-induced lung injury.
- Uridine promoted M2 polarization of alveolar macrophages accompanied by STAT6 phosphorylation, implicating this pathway.
Methodological Strengths
- Integrated in vivo (mouse LPS-ALI) and in vitro (MH-S cells) experiments.
- Multiple orthogonal endpoints including survival and biochemical readouts.
Limitations
- Preclinical LPS model; generalizability to human ARDS is uncertain.
- STAT6 involvement is correlative; no genetic or pharmacologic loss-of-function shown.
- Dosing, exposure, and safety profiling were not detailed.
Future Directions: Test STAT6 dependency using inhibitors or knockouts; validate in diverse ALI/ARDS models and clinically relevant pathogens; perform PK/toxicology and phase I studies.
Acute respiratory distress syndrome (ARDS), the most severe presentation of acute lung injury (ALI), involves diffuse pulmonary inflammation and edema, with hypoxemic respiratory failure as the end result. Given the high mortality and limited therapeutic options, the development of novel interventions is urgently needed. Effective control of excessive pulmonary inflammation and modulation of alveolar macrophage polarization play critical roles in disease progression. In this study, we investigated the therapeutic potential of uridine in alleviating ALI. An in vivo model was established by intratracheal administration of lipopolysaccharide (LPS) in mice, and in vitro experiments were performed using LPS-stimulated MH-S cells. Our results demonstrated that uridine treatment significantly attenuated LPS-induced lung injury, as evidenced by reduced lung index (LI), wet-to-dry weight ratio (W/D), myeloperoxidase (MPO) activity, protein leakage and pro-inflammatory cytokine levels in lung tissues and bronchoalveolar lavage fluid (BALF), along with improved survival in mice. Mechanistically, uridine‑induced M2 polarization of alveolar macrophages was accompanied by STAT6 phosphorylation, suggesting a potential involvement of this pathway. Collectively, these findings suggest that uridine may serve as a promising adjunctive therapeutic agent for ALI, potentially improving disease outcomes through the induction of M2 macrophage polarization.
2. The effect of intracranial pressure monitoring on severe traumatic brain injury patients who undergo subdural hematoma evacuation.
In 3,932 severe TBI patients undergoing SDH evacuation, ICP monitoring showed no reduction in in-hospital mortality after propensity matching (41.6% vs 41.9%, p=0.9) but was associated with longer LOS and higher complication rates (including VAP, DVT, and ARDS). Findings suggest indication refinement and protocol standardization are needed.
Impact: A large, risk-adjusted national cohort challenges guideline-endorsed ICP monitoring for a defined surgical subgroup, highlighting potential iatrogenic burden.
Clinical Implications: Clinicians should weigh the lack of mortality benefit against longer LOS and complications when considering ICP monitoring in severe TBI with SDH evacuation. Prospective trials and standardized care bundles are needed.
Key Findings
- After propensity score matching (n=1271 per group), in-hospital mortality was similar with vs without ICP monitoring (41.6% vs 41.9%, p=0.9).
- ICP monitoring was associated with longer hospital LOS (median 19 vs 13 days, p<0.001).
- Higher rates of complications, including ventilator-associated pneumonia, deep venous thrombosis, and ARDS, occurred in the monitored cohort.
Methodological Strengths
- Large national registry with clearly defined inclusion criteria (GCS 3–8, SDH evacuation).
- Propensity score matching with matched and unmatched analyses.
Limitations
- Retrospective design with potential residual confounding and selection bias.
- Lack of functional/long-term outcomes and details of ICP management protocols.
- Registry data may misclassify complications or timing.
Future Directions: Conduct prospective pragmatic trials or registries with standardized ICP protocols, and assess patient-centered outcomes to identify subgroups benefiting from monitoring.
Intracranial pressure (ICP) monitoring is frequently employed for patients with severe traumatic brain injury. The effect of intracranial pressure monitoring on patient outcomes has been studied little, and results often fail to account for confounding variables. We sought to focus on the impact of ICP monitoring on patients with severe traumatic brain injury and subdural hematoma (SDH) that underwent surgical intervention. Using the National Trauma Data Bank, we identified patients between 2021 and 2024 who had SDH and a presenting Glasgow Coma Score (GCS) of 3-8 who underwent an SDH evacuation. Of the patients whose ICP monitoring status was known, we compared the in-hospital mortality rate and length of stay (LOS) of patients who had ICP monitoring and those who did not. 3932 patients met the inclusion criteria, with 1481 patients undergoing ICP monitoring and 2451 not undergoing ICP monitoring. After propensity score matching to control for confounding variables, 1271 patients from each cohort were selected for further analysis. In-hospital mortality rate of the patients with monitoring did not show a significant difference from the cohort without ICP monitoring, in either matched (41.6% vs. 41.9%, p = 0.9) or without matching scenario (40.2% vs. 42.6%, p = 0.15). However, patients with ICP monitoring showed a longer hospital stay compared to the cohort without ICP monitoring (median 19 days vs. 13 days, p < 0.001). While ICP monitoring is recommended in brain injury treatment guidelines, it did not show a significant impact on the in-hospital mortality rate of patients with SDH and GCS 3-8 who had undergone SDH evacuation. Patients with ICP monitoring had significantly longer LOS and a higher rate of complications, including ventilator-associated pneumonia, deep venous thrombosis, and acute respiratory distress syndrome. Additional study is needed to determine if ICP monitoring improves outcomes in various populations of traumatic brain injury patients. Clinical trial number: not applicable.
3. Role of uridine triggering M2 macrophage polarization to alleviate LPS-induced acute lung injury through the STAT6 signaling pathway.
Uridine attenuated LPS-induced lung injury across physiologic and biochemical endpoints and improved survival; concurrent STAT6 phosphorylation aligns with M2 macrophage polarization as a putative mechanism. Findings motivate STAT6-focused validation and translational dosing studies.
Impact: By converging survival benefit with a defined immunologic pathway, the study offers a mechanistically anchored candidate for ALI/ARDS adjunct therapy.
Clinical Implications: Supports exploration of uridine as an adjunct in ALI/ARDS pending confirmation of STAT6 causality and safety pharmacology.
Key Findings
- Significant attenuation of LPS-induced lung injury metrics (lung index, wet-to-dry ratio, MPO activity, protein leakage, cytokines).
- Improved survival in LPS-injured mice receiving uridine.
- M2 polarization of alveolar macrophages occurred with STAT6 phosphorylation, indicating pathway involvement.
Methodological Strengths
- Concordant in vivo and in vitro findings support biological plausibility.
- Survival as a hard endpoint strengthens translational relevance.
Limitations
- Causality for STAT6 not proven by genetic/pharmacologic perturbation.
- Single-injury LPS model may not capture clinical ARDS heterogeneity.
Future Directions: Establish STAT6 causality, define dosing/exposure-response, and evaluate across pathogen- and ventilator-induced lung injury models.
Acute respiratory distress syndrome (ARDS), the most severe presentation of acute lung injury (ALI), involves diffuse pulmonary inflammation and edema, with hypoxemic respiratory failure as the end result. Given the high mortality and limited therapeutic options, the development of novel interventions is urgently needed. Effective control of excessive pulmonary inflammation and modulation of alveolar macrophage polarization play critical roles in disease progression. In this study, we investigated the therapeutic potential of uridine in alleviating ALI. An in vivo model was established by intratracheal administration of lipopolysaccharide (LPS) in mice, and in vitro experiments were performed using LPS-stimulated MH-S cells. Our results demonstrated that uridine treatment significantly attenuated LPS-induced lung injury, as evidenced by reduced lung index (LI), wet-to-dry weight ratio (W/D), myeloperoxidase (MPO) activity, protein leakage and pro-inflammatory cytokine levels in lung tissues and bronchoalveolar lavage fluid (BALF), along with improved survival in mice. Mechanistically, uridine‑induced M2 polarization of alveolar macrophages was accompanied by STAT6 phosphorylation, suggesting a potential involvement of this pathway. Collectively, these findings suggest that uridine may serve as a promising adjunctive therapeutic agent for ALI, potentially improving disease outcomes through the induction of M2 macrophage polarization.